The 100 Days Mission—2022 Global Pandemic Preparedness Summit

ABSTRACT

Summit participants also noted that regulators must come to a consensus regarding requirements for clinical trial data, become more familiar with technology platforms through review of data across various pathogens over time, and provide guidance on the feasibility of alternative pathways to emergency use approval, especially in the context of the 100 Days Mission (10). Speakers shared reports of progress being made on several fronts the World Health Organization (WHO) and partners are setting up mRNA vaccine technology transfer hubs in South America (12) and South Africa (13);Moderna (https//www.modernatx.com) plans to set up an mRNA manufacturing facility in Kenya (14);SK bioscience (https//www.skbioscience.com) plans to produce routine vaccines in preparation for Disease X that can quickly transfer to large-scale manufacturing if a new pandemic occurs;and WHO has designated South Korea as a biomanufacturing training hub (15). More tools and innovations that enable rapid R&D and manufacturing responses will, in turn, be needed, including standardized animal models and assays, accelerated trial designs, improved rapid diagnostics, laboratory and clinical trial networks that enable data sharing, and distributed manufacturing across regions. March 8, 2022 [cited 2022 Jun 7]. https//www.reuters.com/business/healthcare-pharmaceuticals/moderna-build-mrna-vaccine-manufacturing-facility-kenya-2022-03-07/ World Health Organization.